Braskem SA ADR (BAK)

Total Liabilities

R$92.33B

Quarterly · Period ending: · BRL

BAK logo

BAK Total Liabilities

Latest reportedR$92.33B BRL
BAK Quarterly Total Liabilities · BRL (R$1.46B → R$92.33B)
High-resolution chart · PNG

BAK total liabilities history

Quarterly · BRL. Dates are reporting period ends; fiscal years can differ from calendar years.

Braskem SA ADR Total Liabilities — Quarterly (BRL)
Period endingTotal Liabilities (BRL)
92,327,000,000
90,973,308,000
98,381,000,000
90,556,000,000
94,561,000,000
99,217,000,000
105,853,000,000
94,143,000,000
98,027,000,000
91,174,000,000
88,462,000,000
17,509,252,377
16,846,224,502
16,428,488,930
81,941,000,000
15,785,243,073
16,021,115,222
16,128,478,203
86,360,540,000
15,287,456,000
16,095,963,609
16,934,309,764
17,317,476,608
16,421,875,293
16,371,703,212
15,432,850,807
15,955,535,088
59,258,763,000
56,240,383,000
54,242,888,000
53,282,737,000
54,379,468,000
53,307,552,000
45,473,049,000
47,259,044,000
46,183,927,000
48,832,116,000
47,530,727,000
50,630,821,000
48,708,969,000
47,721,612,000
53,212,853,000
59,681,411,000
58,137,147,000
47,870,733,000
50,558,385,000
43,527,401,000
41,484,627,000
38,131,100,000
38,197,230,000
39,134,456,000
37,610,633,000
35,740,333,000
33,393,141,000
32,517,982,000
32,340,473,000
31,757,515,000
29,525,769,000
27,402,943,000
26,842,413,000
24,004,818,000
23,916,669,000
24,069,205,000
23,354,958,000
24,305,605,000
18,134,992,000
17,604,800,000
16,447,000,000
17,229,000,000
18,726,682,000
19,022,100,000
16,540,628,000
14,611,196,900
14,607,666,284
14,535,803,110
12,067,752,962
12,760,282,967
11,380,080,852
11,941,673,727
11,772,704,721
10,752,445,620
10,591,379,460
10,926,973,313
10,444,092,615
10,784,026,512
10,377,947,552
10,505,079,102
12,147,538,320
12,579,975,306
13,877,378,870
11,170,697,339
10,854,639,958
10,072,344,000
12,149,366,902
11,284,015,187
8,381,555,578
3,742,045,276
3,135,532,134
3,104,982,446
3,619,833,466
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.